{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:57:16Z","timestamp":1790575036521,"version":"4.1.0"},"reference-count":122,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Statins remain the cornerstone of pharmacological prevention for atherosclerotic cardiovascular disease (ASCVD) because of their proven ability to reduce low-density lipoprotein cholesterol (LDL-C) and major adverse cardiovascular events (MACE). However, many patients continue to experience ASCVD events despite achieving guideline-recommended LDL-C targets with maximally tolerated statin therapy, highlighting the persistence of residual ASCVD risk. This scoping review synthesized current evidence on residual ASCVD risk in statin-treated patients, focusing on its epidemiology, underlying mechanisms, clinical evidence, therapeutic strategies beyond statins, and barriers to optimal risk reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A scoping review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) guidelines. Electronic databases were systematically searched, yielding 1,240 records. After duplicate removal and screening, 195 full-text articles were assessed for eligibility, and 35 studies were included in the final qualitative synthesis. The included evidence comprised randomized controlled trials, observational cohort studies, registry-based investigations, and systematic and narrative reviews.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The included studies were synthesized into five major themes: epidemiology of residual ASCVD risk, underlying mechanisms, clinical evidence from landmark trials and real-world studies, therapeutic strategies beyond statins, and challenges limiting effective risk reduction. Evidence consistently demonstrated that residual ASCVD risk persists despite substantial LDL-C reduction because of multiple interacting factors, including elevated triglyceride-rich remnant lipoproteins, lipoprotein(a), persistent inflammation, metabolic comorbidities, vascular aging, treatment-implementation barriers, and behavioral factors. Landmark clinical trials, including IMPROVE-IT, FOURIER, ODYSSEY OUTCOMES, REDUCE-IT, CANTOS, LoDoCo2, and CLEAR Outcomes, demonstrated incremental cardiovascular benefit from combination lipid-lowering and selected anti-inflammatory therapies, while emerging therapies targeting lipoprotein(a), IL-6 signaling, and RNA-based pathways offer promising strategies for further reducing residual ASCVD risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Residual ASCVD risk remains a major challenge despite guideline-directed statin therapy. Effective risk reduction requires a comprehensive approach that extends beyond LDL-C lowering to include combination lipid-lowering therapy, inflammation-targeted interventions, lifestyle optimization, improved treatment adherence, and individualized risk assessment. Continued evaluation of emerging therapies and precision medicine approaches is essential to further reduce the global burden of ASCVD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1911458","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:44:51Z","timestamp":1790574291000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Residual atherosclerotic cardiovascular disease risk in statin-treated patients: mechanisms, therapeutic strategies, and future directions\u2014a scoping review"],"prefix":"10.3389","volume":"13","author":[{"given":"Muhammad","family":"Abdul Rehman","sequence":"first","affiliation":[{"name":"Department of Medicine, Nawaz Sharif Medical College (NSMC)","place":["Gujrat, Punjab, Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik Olatunde","family":"Oduoye","sequence":"additional","affiliation":[{"name":"Department of Research, The Medical Research Circle","place":["Goma, Democratic Republic of Congo"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davidson John","family":"Ozoemena","sequence":"additional","affiliation":[{"name":"Department of Physiology, School of Medicine, Wayne State University","place":["Michigan, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Akosah Danso","sequence":"additional","affiliation":[{"name":"Department of Surgery, Korle-Bu Teaching Hospital","place":["Accra, Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Chukwuka","sequence":"additional","affiliation":[{"name":"Department of Laboratory Services, Federal Medical Center","place":["Abuja, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Abosede","family":"Odelade","sequence":"additional","affiliation":[{"name":"Department of Nursing and Health, State University of Southwest Bahia","place":["Jequie, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/eurjpc\/zwae281","article-title":"Global burden of cardiovascular diseases: projections from 2025 to 2050","volume":"32","author":"Chong","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"843","DOI":"10.2147\/VHRM.S9474","article-title":"Benefits of statin therapy and compliance in high risk cardiovascular patients","volume":"6","author":"Lardizabal","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.3390\/jcm14072352","article-title":"Beyond cholesterol: emerging risk factors in atherosclerosis","volume":"14","author":"Bekbossynova","year":"2025","journal-title":"J Clin Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.cjca.2015.06.028","article-title":"The burden of cardiovascular disease in low- and middle-income countries: epidemiology and management","volume":"31","author":"Bowry","year":"2015","journal-title":"Can J Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100130","DOI":"10.1016\/j.ajpc.2020.100130","article-title":"Inflammation and cardiovascular disease: from mechanisms to therapeutics","volume":"4","author":"Alfaddagh","year":"2020","journal-title":"Am J Prev Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"114960","DOI":"10.4330\/wjc.v18.i2.114960","article-title":"Residual risk in atherosclerotic cardiovascular disease after statin therapy: clinical mechanisms and management strategies","volume":"18","author":"Tan","year":"2026","journal-title":"World J Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1007\/s00392-022-02147-3","article-title":"Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (\u201cJena auf Ziel\u201d)","volume":"112","author":"Makhmudova","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1093\/eurheartj\/ehag087","article-title":"Residual lipid risk in atherosclerotic cardiovascular disease","volume":"47","author":"Nordestgaard","year":"2026","journal-title":"Eur Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"24F","DOI":"10.1016\/j.amjcard.2005.06.009","article-title":"Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol","volume":"96","author":"Liao","year":"2005","journal-title":"Am J Cardiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1194\/jlr.M049429","article-title":"A novel posttranscriptional mechanism for dietary cholesterol-mediated suppression of liver LDL receptor expression","volume":"55","author":"Singh","year":"2014","journal-title":"J Lipid Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"100649","DOI":"10.1016\/j.ajpc.2024.100649","article-title":"The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: lower for longer is better","volume":"18","author":"Mhaimeed","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"100574","DOI":"10.1016\/j.athplu.2026.100574","article-title":"LDL-cholesterol distance to target: a practical tool for guiding lipid-lowering treatment decisions","volume":"65","author":"Palloni","year":"2026","journal-title":"Atheroscler Plus"},{"key":"B13","doi-asserted-by":"publisher","first-page":"108342","DOI":"10.1016\/j.phrs.2026.108342","article-title":"Beyond lipid lowering: targeting lncRNAs as a novel therapeutic strategy for vascular wall defense in atherosclerosis","volume":"231","author":"Chen","year":"2026","journal-title":"Pharmacol Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3390\/jcdd10060260","article-title":"Effects of lipid lowering therapies on vulnerable plaque features: an updated narrative review of the literature","volume":"10","author":"Biccir\u00e8","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jcmg.2024.12.004","article-title":"Vulnerable or high-risk plaque: a JACC: cardiovascular imaging position statement","volume":"18","author":"Vergallo","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"B16","doi-asserted-by":"publisher","first-page":"100236","DOI":"10.1016\/j.mtbio.2022.100236","article-title":"Current advances in the imaging of atherosclerotic vulnerable plaque using nanoparticles","volume":"14","author":"Zhang","year":"2022","journal-title":"Mater Today Bio"},{"key":"B17","doi-asserted-by":"publisher","first-page":"200198","DOI":"10.1016\/j.ijcrp.2023.200198","article-title":"Residual cardiovascular risk, use of standard care treatments, and achievement of treatment goals in patients with cardiovascular disease","volume":"18","author":"Siniawski","year":"2023","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3390\/pharmaceutics16020214","article-title":"Potential benefits and risks associated with the use of statins","volume":"16","author":"Khatiwada","year":"2024","journal-title":"Pharmaceutics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3390\/jcm13051251","article-title":"Novel and emerging LDL-C lowering strategies: a new era of dyslipidemia management","volume":"13","author":"Agnello","year":"2024","journal-title":"J Clin Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1330","DOI":"10.1016\/S2214-109X(25)00223-2","article-title":"Low risk, high impact: the hidden burden of cardiovascular disease","volume":"13","author":"Tang","year":"2025","journal-title":"Lancet Glob Heal"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1007\/s11427-025-2948-y","article-title":"Global burden of atherosclerotic cardiovascular disease attributed to lifestyle and metabolic risks","volume":"68","author":"Xu","year":"2025","journal-title":"Sci China Life Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.jacc.2025.08.015","article-title":"Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990\u20132023. JACC 86, no. 22","year":"2025"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41569-026-01249-z","article-title":"Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies","volume":"23","author":"Galli","year":"2026","journal-title":"Nat Rev Cardiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2147\/VHRM.S37119","article-title":"Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes","volume":"9","author":"Kones","year":"2013","journal-title":"Vasc Health Risk Manag"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e685","DOI":"10.1016\/j.jacl.2024.07.001","article-title":"Addressing residual risk beyond statin therapy: new targets in the management of dyslipidaemias\u2014a report from the European Society of Cardiology cardiovascular round table","volume":"18","author":"Mach","year":"2024","journal-title":"J Clin Lipidol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1403363","DOI":"10.3389\/fcvm.2024.1403363","article-title":"First manifestation of cardiovascular disease according to age and sex in a Mediterranean country","volume":"11","author":"Ortega","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/jcdd6020019","article-title":"Cardiovascular risks associated with gender and aging","volume":"6","author":"Rodgers","year":"2019","journal-title":"J Cardiovasc Dev Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s12020-024-03772-w","article-title":"Early onset type 2 diabetes mellitus: an update","volume":"85","author":"Strati","year":"2024","journal-title":"Endocrine"},{"key":"B33","doi-asserted-by":"publisher","first-page":"107","DOI":"10.14797\/mdcvj.1328","article-title":"Sex disparities in cardiovascular disease","volume":"20","author":"Mahowald","year":"2024","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s40265-016-0613-0","article-title":"Unmet needs in LDL-C lowering: when statins won\u2019t do!","volume":"76","author":"Kr\u00e4henb\u00fchl","year":"2016","journal-title":"Drugs"},{"key":"B35","doi-asserted-by":"publisher","first-page":"E442","DOI":"10.1503\/cmaj.241713","article-title":"Clinical significance of low-density lipoprotein cholesterol percentage reduction and attained levels after percutaneous coronary intervention","volume":"197","author":"Kang","year":"2025","journal-title":"Can Med Assoc J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.12997\/jla.2025.14.3.247","article-title":"Triglycerides, triglyceride-rich lipoproteins, and remnant cholesterol in atherosclerotic cardiovascular disease","volume":"14","author":"Jo","year":"2025","journal-title":"J Lipid Atheroscler"},{"key":"B37","doi-asserted-by":"publisher","first-page":"100641","DOI":"10.1016\/j.ajpc.2024.100641","article-title":"Lipoprotein(a): emerging insights and therapeutics","volume":"18","author":"Kaur","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0294250","DOI":"10.1371\/journal.pone.0294250","article-title":"Burden of elevated lipoprotein(a) among patients with atherosclerotic cardiovascular disease: evidence from a systematic literature review and feasibility assessment of meta-analysis","volume":"18","author":"Orfanos","year":"2023","journal-title":"PLoS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12872-022-02663-0","article-title":"High-sensitivity C-reactive protein and low-density lipoprotein cholesterol association with incident of cardiovascular events: Isfahan cohort study","volume":"22","author":"Nafari","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1409653","DOI":"10.3389\/fendo.2024.1409653","article-title":"Triglyceride-rich lipoproteins and cardiovascular diseases","volume":"15","author":"Xu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2631606","DOI":"10.1080\/10641963.2026.2631606","article-title":"Mechanisms linking hypertension to cardiovascular and cerebrovascular diseases and their clinical implications: a comprehensive review","volume":"48","author":"Li","year":"2026","journal-title":"Clin Exp Hypertens"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e003665","DOI":"10.1161\/JAHA.116.003665","article-title":"Age and cardiovascular risk attributable to apolipoprotein B, low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol","volume":"5","author":"Sniderman","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"B43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/clinchem\/hvaa252","article-title":"Residual cardiovascular risk at low LDL: remnants, lipoprotein(a), and inflammation","volume":"67","author":"Hoogeveen","year":"2021","journal-title":"Clin Chem"},{"key":"B44","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41392-022-01125-5","article-title":"Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics","volume":"7","author":"Duan","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B45","doi-asserted-by":"publisher","first-page":"120529","DOI":"10.1016\/j.atherosclerosis.2025.120529","article-title":"Triglyceride-rich lipoproteins, remnants and atherosclerotic cardiovascular disease: what we know and what we need to know","volume":"410","author":"Chapman","year":"2025","journal-title":"Atherosclerosis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.3346\/jkms.2023.38.e295","article-title":"Triglyceride-rich lipoproteins and remnant cholesterol in cardiovascular disease","volume":"38","author":"Heo","year":"2023","journal-title":"J Korean Med Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e005549","DOI":"10.1161\/JAHA.117.005549","article-title":"Atherogenic lipoprotein determinants of cardiovascular disease and residual risk among individuals with low low-density lipoprotein cholesterol","volume":"6","author":"Lawler","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"B48","doi-asserted-by":"publisher","first-page":"6721","DOI":"10.3390\/ijerph20186721","article-title":"Lipoprotein(a) as a risk factor for cardiovascular diseases: pathophysiology and treatment perspectives","volume":"20","author":"Vinci","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"B49","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van Der Valk","year":"2016","journal-title":"Circulation"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e07","DOI":"10.15420\/ecr.2025.66","article-title":"Presumed mechanisms underlying lipoprotein(a)-caused atherosclerosis","volume":"21","author":"Filtz","year":"2026","journal-title":"Eur Cardiol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"879021","DOI":"10.3389\/fnagi.2022.879021","article-title":"The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases","volume":"14","author":"Blevins","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: mechanism of action, role in disease, and therapeutics","volume":"21","author":"Guo","year":"2015","journal-title":"Nat Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"23362","DOI":"10.1038\/s41598-025-05903-3","article-title":"Trimethylamine-N-oxide (TMAO) and risk of incident cardiovascular events in the multi ethnic study of atherosclerosis","volume":"15","author":"Budoff","year":"2025","journal-title":"Sci Rep"},{"key":"B54","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3390\/metabo15040220","article-title":"Trimethylamine-N-oxide (TMAO) as a rising-star metabolite: implications for human health","volume":"15","author":"Caradonna","year":"2025","journal-title":"Metabolites"},{"key":"B55","doi-asserted-by":"publisher","first-page":"7432","DOI":"10.3390\/jcm12237432","article-title":"Evolution of more aggressive LDL-cholesterol targets and therapies for cardiovascular disease prevention","volume":"12","author":"Jones","year":"2023","journal-title":"J Clin Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"633","DOI":"10.21037\/cdt.2017.04.06","article-title":"The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention","volume":"7","author":"Kotseva","year":"2017","journal-title":"Cardiovasc Diagn Ther"},{"key":"B57","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12944-025-02607-5","article-title":"Elevated remnant cholesterol and triglycerides are predictors of increased total mortality in a primary health care population of 327,347 patients","volume":"24","author":"Engell","year":"2025","journal-title":"Lipids Health Dis"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1529223","DOI":"10.3389\/fnut.2025.1529223","article-title":"Lipoprotein cholesterol ratios and cardiovascular disease risk in US adults: a cross-sectional study","volume":"12","author":"Yang","year":"2025","journal-title":"Front Nutr"},{"key":"B59","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12944-025-02850-w","article-title":"Cumulative average remnant cholesterol inflammatory index and risk of cardiometabolic multimorbidity: evidence from a prospective nationwide cohort study in China","volume":"25","author":"Zhang","year":"2026","journal-title":"Lipids Health Dis"},{"key":"B60","doi-asserted-by":"publisher","first-page":"135","DOI":"10.31083\/j.rcm2304135","article-title":"Aging and cardiovascular disease: current status and challenges","volume":"23","author":"Zhou","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4103\/jmh.JMH_20_20","article-title":"Atypical manifestations of women presenting with myocardial infarction at tertiary health care center: an analytical study","volume":"12","author":"Joseph","year":"2021","journal-title":"J Midlife Health"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4314\/ejhs.v35i1.1","article-title":"Increase in cardiovascular disease mortality in low- and middle-income countries: a time for action","volume":"35","author":"Asefa","year":"2025","journal-title":"Ethiop J Health Sci"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1680745","DOI":"10.3389\/fpubh.2025.1680745","article-title":"About half of older adults have two or more chronic conditions at the same time: a systematic review and meta-analysis","volume":"13","author":"Zhu","year":"2025","journal-title":"Front Public Health"},{"key":"B64","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2147\/DMSO.S390857","article-title":"The interaction between age and risk factors for diabetes and prediabetes: a community-based cross-sectional study","volume":"16","author":"Yan","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B65","doi-asserted-by":"publisher","first-page":"10","DOI":"10.15420\/ecr.2016:32:1","article-title":"Cardiovascular disease in women: understanding symptoms and risk factors","volume":"12","author":"Keteepe-Arachi","year":"2017","journal-title":"Eur Cardiol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"20220759","DOI":"10.1515\/biol-2022-0759","article-title":"Role of menopausal hormone therapy in the prevention of postmenopausal osteoporosis","volume":"18","author":"Na","year":"2023","journal-title":"Open Life Sci"},{"key":"B67","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.2147\/DMSO.S540103","article-title":"Obesity and its comorbidities: current treatment options, emerging biological mechanisms, future perspectives and challenges","volume":"18","author":"Wang","year":"2025","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B68","doi-asserted-by":"publisher","first-page":"101324","DOI":"10.1016\/j.ajpc.2025.101324","article-title":"Systemic inflammation modulates lipoprotein(a)-associated coronary stenosis in the chronic coronary syndromes","volume":"24","author":"Shen","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"212534","DOI":"10.7573\/dic.212534","article-title":"Adding ezetimibe to statin therapy: latest evidence and clinical implications","volume":"7","author":"Vavlukis","year":"2018","journal-title":"Drugs Context"},{"key":"B70","doi-asserted-by":"publisher","first-page":"104465","DOI":"10.1016\/j.numecd.2025.104465","article-title":"Gut microbiota profiles by LDL-C target achievement in statin-treated patients: a cross-sectional study","volume":"36","author":"Liu","year":"2026","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3390\/pharmaceutics16111371","article-title":"Bempedoic acid, the first-in-class oral ATP citrate lyase inhibitor with hypocholesterolemic activity: clinical pharmacology and drug-drug interactions","volume":"16","author":"Ferri","year":"2024","journal-title":"Pharmaceutics"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"8129513","DOI":"10.1155\/2022\/8129513","article-title":"Advantages and disadvantages of inclisiran: a small interfering ribonucleic acid molecule targeting PCSK9-A narrative review","volume":"2022","author":"Mer\u0107ep","year":"2022","journal-title":"Cardiovasc Ther"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","article-title":"Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial","volume":"120","author":"Wright","year":"2024","journal-title":"Cardiovasc Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"119301","DOI":"10.1016\/j.biopha.2026.119301","article-title":"Immune\u2013endothelial crosstalk in cardiovascular inflammation: canakinumab at the intersection of mechanism and precision therapy","volume":"198","author":"Srivastava","year":"2026","journal-title":"Biomed Pharmacother"},{"key":"B76","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1161\/HYPERTENSIONAHA.119.13642","article-title":"Effects of interleukin-1\u03b2 inhibition on blood pressure, incident hypertension, and residual inflammatory risk: a secondary analysis of CANTOS","volume":"75","author":"Rothman","year":"2020","journal-title":"Hypertension"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e038687","DOI":"10.1161\/JAHA.124.038687","article-title":"Cardiovascular benefit of colchicine in relation to baseline risk: a secondary analysis of the LoDoCo2 trial","volume":"14","author":"Mohammadnia","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"B78","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11886-025-02337-1","article-title":"Targeting triglycerides in cardiovascular disease prevention: evidence, mechanisms, and emerging therapies","volume":"28","author":"Alam","year":"2026","journal-title":"Curr Cardiol Rep"},{"key":"B80","doi-asserted-by":"publisher","first-page":"100350","DOI":"10.1016\/j.ahjo.2023.100350","article-title":"Lipoprotein(a): an important piece of the ASCVD risk factor puzzle across diverse populations","volume":"38","author":"Ciffone","year":"2024","journal-title":"Am Hear J Plus Cardiol Res Pract"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1758366","DOI":"10.3389\/fcvm.2026.1758366","article-title":"Efficacy and safety of lipoprotein(a)-targeted therapeutics: a systematic review and network meta-analysis","volume":"13","author":"Hu","year":"2026","journal-title":"Front Cardiovasc Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.jacc.2021.01.051","article-title":"Emerging RNA therapeutics to lower blood levels of Lp(a): JACC Focus Seminar 2\/4","volume":"77","author":"Tsimikas","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.jacl.2025.06.004","article-title":"Pelacarsen: mechanism of action and Lp(a)-lowering effect","volume":"19","author":"Bhatia","year":"2025","journal-title":"J Clin Lipidol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.3390\/jcm15135233","article-title":"Emerging therapies targeting lipoprotein(a): a clinical trial landscape review of investigational Lp(a)-lowering therapies","volume":"15","author":"Alotaibi","year":"2026","journal-title":"J Clin Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/13543784.2023.2267972","article-title":"MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment","volume":"32","author":"Burnett","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","article-title":"Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616","volume":"81","author":"Ballantyne","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s12325-025-03418-x","article-title":"Lipid-lowering efficacy and safety of oral proprotein convertase subtilisin\/kexin type 9 inhibitors: a systematic review and meta-analysis","volume":"43","author":"Masson","year":"2026","journal-title":"Adv Ther"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwag273","article-title":"Efficacy and safety of oral PCSK9 inhibitors: insights from a meta-analysis of RCTS","author":"Olmastroni","year":"2026","journal-title":"Eur J Prev Cardiol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"101659","DOI":"10.1016\/j.ajpc.2026.101659","article-title":"Oral PCSK9 inhibitors for elevated LDL-C: a systematic review and meta-analysis of randomized trials","volume":"28","author":"Karthikeyan","year":"2026","journal-title":"Am J Prev Cardiol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1001\/jamacardio.2022.4277","article-title":"Association of interleukin 6 inhibition with ziltivekimab and the neutrophil-lymphocyte ratio: a secondary analysis of the RESCUE clinical trial","volume":"8","author":"Adamstein","year":"2023","journal-title":"JAMA Cardiol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jjcc.2023.05.006","article-title":"Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"82","author":"Wada","year":"2023","journal-title":"J Cardiol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ijcard.2016.09.075","article-title":"Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement","volume":"225","author":"Banach","year":"2016","journal-title":"Int J Cardiol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/VHRM.S158641","article-title":"Nonadherence to statins: individualized intervention strategies outside the pill box","volume":"14","author":"Lansberg","year":"2018","journal-title":"Vasc Health Risk Manag"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e0295857","DOI":"10.1371\/journal.pone.0295857","article-title":"Intolerance upon statin rechallenge: a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Kraut","year":"2023","journal-title":"PLoS One"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.n135","article-title":"Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials","volume":"372","author":"Herrett","year":"2021","journal-title":"Br Med J"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","article-title":"Side effect patterns in a crossover trial of statin, placebo, and no treatment","volume":"78","author":"Howard","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jacl.2024.10.010","article-title":"Clinical impact of \u226550% reduction of low density lipoprotein cholesterol following lipid lowering therapy on cardiovascular outcomes in patients with acute coronary syndrome","volume":"19","author":"Fujioka","year":"2025","journal-title":"J Clin Lipidol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"e011765","DOI":"10.1161\/JAHA.118.011765","article-title":"Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM Registry","volume":"8","author":"Bradley","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"B99","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bcp.13797","article-title":"Predictors of first-year nonadherence and discontinuation of statins among older adults: a retrospective cohort study","volume":"85","author":"Ofori-Asenso","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"e033992","DOI":"10.1161\/JAHA.124.033992","article-title":"Social media posts on statins: what can we learn about patient experiences and perspectives?","volume":"13","author":"Golder","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"B101","doi-asserted-by":"publisher","first-page":"101289","DOI":"10.1016\/j.ajpc.2025.101289","article-title":"The impact of health misinformation and health literacy on the management of dyslipidemia","volume":"24","author":"Johnson","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11883-012-0291-7","article-title":"How do we improve patient compliance and adherence to long-term statin therapy?","volume":"15","author":"Maningat","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"B103","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40256-023-00594-5","article-title":"Established and emerging lipid-lowering drugs for primary and secondary cardiovascular prevention","volume":"23","author":"Michaeli","year":"2023","journal-title":"Am J Cardiovasc Drugs"},{"key":"B104","doi-asserted-by":"publisher","first-page":"100701","DOI":"10.1016\/j.ajpc.2024.100701","article-title":"Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond","volume":"19","author":"Safarova","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"e69900","DOI":"10.7759\/cureus.69900","article-title":"A comparative analysis of low-density lipoprotein cholesterol (LDL-C)-lowering activities of bempedoic acid, inclisiran, and PCSK9 inhibitors: a systematic review","volume":"16","author":"Rajendran","year":"2024","journal-title":"Cureus"},{"key":"B106","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3390\/jcdd12050196","article-title":"Therapeutic management of LDL-C: efficacy and economic impact assessment","volume":"12","author":"Elshafeey","year":"2025","journal-title":"J Cardiovasc Dev Dis"},{"key":"B107","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1177\/2047487318825350","article-title":"Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry","volume":"26","author":"Kotseva","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1161\/CIRCRESAHA.117.310782","article-title":"Emerging role of precision medicine in cardiovascular disease","volume":"122","author":"Leopold","year":"2018","journal-title":"Circ Res"},{"key":"B110","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/1753-0407.12769","article-title":"Patterns of statin use and long-term adherence and persistence among older adults with diabetes","volume":"10","author":"Ofori-Asenso","year":"2018","journal-title":"J Diabetes"},{"key":"B111","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"B112","doi-asserted-by":"publisher","first-page":"517","DOI":"10.4093\/dmj.2022.0198","article-title":"New, novel lipid-lowering agents for reducing cardiovascular risk: beyond statins","volume":"46","author":"Kim","year":"2022","journal-title":"Diabetes Metab J"},{"key":"B113","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41569-023-00860-8","article-title":"Novel and future lipid-modulating therapies for the prevention of cardiovascular disease","volume":"20","author":"Brandts","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12944-024-02078-0","article-title":"The effect of lipid-lowering therapy on lipid-related residual risk factors: a prospective study","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1461416","DOI":"10.3389\/fcvm.2025.1461416","article-title":"Treatment adherence, persistence, and effectiveness of fixed dose combination versus free combination therapy of rosuvastatin-ezetimibe as a lipid-lowering therapy","volume":"12","author":"Samnaliev","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"B116","doi-asserted-by":"publisher","first-page":"25755","DOI":"10.1038\/s41598-024-77352-3","article-title":"Biomarker identification and risk assessment of cardiovascular disease based on untargeted metabolomics and machine learning","volume":"14","author":"Zhou","year":"2024","journal-title":"Sci Rep"},{"key":"B117","doi-asserted-by":"publisher","first-page":"6773","DOI":"10.3390\/jcm11226773","article-title":"Recent advances in gene therapy for familial hypercholesterolemia: an update review","volume":"11","author":"Fu","year":"2022","journal-title":"J Clin Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1161\/CIR.0000000000001385","article-title":"Genetic and genomic testing in cardiovascular disease: a policy statement from the American Heart Association","volume":"152","author":"Landstrom","year":"2025","journal-title":"Circulation"},{"key":"B119","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s10557-021-07248-1","article-title":"The combination of beta-blockers and ACE inhibitors across the spectrum of cardiovascular diseases","volume":"37","author":"Strauss","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1656818","DOI":"10.3389\/fcvm.2025.1656818","article-title":"Maximizing blood pressure lowering effects: a review of drug class comparisons and rationale for combination approaches","volume":"12","author":"Yang","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"8429","DOI":"10.3390\/ijms26178429","article-title":"Molecular and immunomodulatory mechanisms of statins in inflammation and cancer therapeutics with emphasis on the NF-\u03baB, NLRP3 inflammasome, and cytokine regulatory axes","volume":"26","author":"Khan","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B122","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet (London, England)"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1911458\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:44:52Z","timestamp":1790574292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1911458\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":122,"alternative-id":["10.3389\/fcvm.2026.1911458"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1911458","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1911458"}}